Phase II
Continuous Monitoring with Wearable Device Detected Distinct Pulse Wave Patterns in Obstructive Hypertrophic Cardiomyopathy Patients as Compared to Healthy Volunteers
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019
Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories.
Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, announced that half of the patients have been enrolled and started the treatment in the company’s Phase II-study with the company’s product candidate LL-37 for treatment of venous leg ulcers.
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
Calithera Biosciences, Inc. announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma.
Medigene AG announced that clinical data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia was presented during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis
TLC, announced results from the pre-planned analysis of Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers
PRESS RELEASES